GlassScriptPhysician profile
Melanie C Ellers
NPI 1558786293
$7,319.68
in general payments reported to CMS, 2019-2025
27 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $172 · 2023: $2,891 · 2024: $2,625 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,141 · Travel and Lodging: $804 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,140.67 |
| Travel and Lodging | $803.69 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,254.09 | 2023-2025 | Intellis Adaptivestim, Synchromedii, Osteocool Rf Ablation System |
| Abbvie INC. | $1,462.23 | 2022-2025 | |
| Saluda Medical Americas, INC. | $1,406.02 | 2023-2025 | Evoke, Evoke Scs |
| Relievant Medsystems, INC. | $636.73 | 2023 | Intracept |
| Abbott Laboratories | $251.76 | 2024-2025 | Eterna |
| Pfizer INC. | $218.90 | 2023-2025 | |
| Tersera Therapeutics LLC | $163.48 | 2023-2025 | Prialt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.90 | 2023-2025 | Relistor |
| Averitas Pharma INC. | $118.02 | 2023-2025 | Qutenza |
| Spr Therapeutics, INC | $96.91 | 2021-2022 | |
| Painteq LLC | $67.00 | 2023-2024 | Painteq |
| Collegium Pharmaceutical, INC. | $65.60 | 2021-2024 | Belbuca |
| Revance Therapeutics, INC. | $55.47 | 2024 | Daxxify |
| Allergan, INC. | $48.08 | 2021 | |
| Djo, LLC | $44.16 | 2024 | Cmf |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38.21 | 2021 | |
| Scilex Pharmaceuticals INC. | $30.60 | 2023-2024 | Ztlido |
| Grt US Holding, INC. | $24.91 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $22.80 | 2025 | Ajovy |
| Fidia Pharma USA INC. | $22.07 | 2024 | Hymovis, Triluron, Hyalgan |
| Lilly USA, LLC | $22.02 | 2025 | Mounjaro, Zepbound |
| Ibsa Pharma INC. | $21.42 | 2023 | Tirosint, Licart |
| Si-Bone, INC. | $20.85 | 2025 | |
| Lundbeck LLC | $20.27 | 2025 | Vyepti |
| Zimmer Biomet Holdings, INC. | $19.86 | 2024 | Gps III Platelet Concentration System |
| Vertex Pharmaceuticals Incorporated | $15.52 | 2025 | |
| Nevro Corp. | $13.80 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Ellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.